Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

Recently, I was diagnosed with BPH. This is all new to me, and I hope you can help me better understand the condition and how ...

The Prostate Cancer Market is set to grow from USD 11.7 Billion in 2022 to USD 21.6 Billion by 2031, driven by rising cases in targeted therapies. The U.S. Prostate Cancer Market is expanding rapidly ...

Prostate cancer is treatable but there’s no way to know if it will return That’s why it’s important to take proactive steps ...

Two cancer survivors are urging others to get checked as their colleagues prepare to take on the Three Peaks in aid of three ...

A tool developed by a scientist at UVA’s School of Nursing can help prostate cancer patients make important decisions when it comes to treatment options.

"Cancer changes you and everyone around you. That’s not a cliché. For me, it brought anxiety, urgency and openness." ...

The Philadelphia Conquering Cancer Coalition aims to remove barriers and improve communication and collaboration between ...

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a ...

Northwell’s Phelps Hospital is the first and only medical facility in New York State between the Bronx and Albany to offer Pluvicto, a groundbreaking treatment for men with advanced prostate […] ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

The American Cancer Society said that prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 3.5 million men in the United States ...